Trials / Completed
CompletedNCT02831660
CU Programme of Idarucizumab for Japanese Patients
A Compassionate Use Program of Idarucizumab for Reversal of the Anticoagulant Effects of Dabigatran in Japanese Patients Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective is to collect the safety data of idarucizumab for patients treated with dabigatran who require rapid reversal of the anticoagulant effects of dabigatran in cases of uncontrolled or life-threatening bleeding or when emergency surgery or urgent procedures are required.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | idarucizumab |
Timeline
- Start date
- 2016-07-22
- Primary completion
- 2016-09-16
- Completion
- 2016-09-16
- First posted
- 2016-07-13
- Last updated
- 2018-03-20
- Results posted
- 2018-03-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02831660. Inclusion in this directory is not an endorsement.